Categories Earnings, Health Care

Sarepta Therapeutics (SRPT): Q4 2019 Earnings Snapshot

Earnings Update by AlphaStreet

—  Sarepta Therapeutics, Inc.  (NASDAQ: SRPT) reported a loss of $1.57 per share in the fourth quarter of 2019, vs $1.86 per share loss expected.

— Q4 revenue rose 19% to $100.1 million, vs. $98.8 million expected. Results were helped by an increase in demand for EXONDYS 51 in the U.S.

— Appointed biotech executive John C. Martin to Board of Directors. He is a former Gilead CEO.

— SRPT shares ended Wednesday’s regular trading session down 1.14%. 

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Most Popular

Important takeaways from Paychex’s (PAYX) Q2 2025 earnings report

Paychex Inc. (NASDAQ: PAYX), a leading provider of human resources and payroll services, reported better-than-expected revenue and profit for the second quarter of fiscal 2025, sending the stock higher soon

Lamb Weston’s (LW) challenges may not end soon, a few points to note

Shares of Lamb Weston Holdings, Inc. (NYSE: LW) turned red in mid-day trade on Friday. The stock has dropped 19% in the past one month. The company delivered disappointing results

CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%

Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top